A Study of JR-141 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II Clinical Trial

Official title:

Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03359213
• Other study ID #: JR-141-BR21
• Status: Completed
• Phase: Phase 2
• Start date: July 26, 2018
• Est. completion date: October 4, 2019

Study information

• Verified date: November 2022
• Source: JCR Pharmaceuticals Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: October 4, 2019
• Est. primary completion date: October 4, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 0 Years and older

Eligibility

Inclusion Criteria:

• Males with confirmed diagnosis of MPS II, based on deficient activity of IDS in leucocytes or fibroblasts and/or pathogenic mutations identified in the IDS gene (if enzyme diagnosis was in dried blood spots or plasma, molecular genetics confirmation is mandatory).

• One of the following age groups:

1. 0 to 3 years and 11 months old (6 patients, 2 in each dose)

2. 4 years to 7 years and 11 months old (6 patients, 2 in each dose)

3. 8 years or older (6 patients, 2 in each dose)

• Capable of providing written consent by himself, unless the patient is under the age of 18 years at the time of informed consent process, or it is not possible to obtain consent from the patient himself due to his intellectual disabilities associated with MPS II.

• In the case of a patient who is under the age of 18 years or from whom it is not possible to obtain consent due to his intellectual disabilities associated with MSP II, he may be included if written consent can be provided by legal representative; however written consent should be obtained from the patient himself too, wherever possible.

• Naïve patients or patients who are receiving enzyme replacement therapy with idursulfase could be included if provided treatment has been stable in the last 6 months and agree to interrupt the treatment at least one week before the first study drug infusion, and agree in suspending this treatment for the duration of the trial.

Exclusion Criteria:

• Refusal to sign the informed consent form.

• Unable to perform the study procedures, except for neurocognitive testing.

• Previous engrafted BMT/HSCT.

• Surgical or other major medical intervention planned to occur before week 26.

• Participation in a clinical trial with an investigational drug in the last 12 months.

• Judged by the investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumber puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process.

• Judged by the investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or sensitivity.

• Otherwise judged by the investigator or subinvestigator to be ineligible to participate in the study out of consideration for the subject safety.

Related Conditions & MeSH terms

• Mucopolysaccharidoses
• Mucopolysaccharidosis II

Intervention

Drug:
• JR-141
IV infusion (lyophilized powder), 1.0 mg/kg/week
• JR-141
IV infusion (lyophilized powder), 2.0 mg/kg/week
• JR-141
IV infusion (lyophilized powder), 4.0 mg/kg/week

Locations

Country	Name	City	State
Brazil	Grupo de Pesquisa Clínica em Genética Médica - HCPA	Porto Alegre
Brazil	Igeim - Unifesp	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
JCR Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events	Adverse events; Antidrug antibodies; Blood pressures in mmHg; Heart rate in beats/minute; Respiratory rate in breaths/minute; Temperature in °C; Presence or absence of abnormalities for physical examination; Presence or absence of abnormalities for 12-lead electrocardiogram; Routine laboratory tests in blood (hematology, liver function, renal function, iron-related levels) and urine (urinalysis)	26 weeks
Secondary	Plasma Pharmacokinetic parameter [Maximum Plasma Concentration [Cmax]]	Plasma concentration of JR-141	21 hours after dosing at the first and last infusions
Secondary	Plasma Pharmacokinetic parameter [Area Under the Curve [AUC]]	Plasma concentration of JR-141	21 hours after dosing at the first and last infusions
Secondary	Liver and spleen volumes (MRI)		26 weeks
Secondary	Left ventricular mass by a standard 2-dimensional Doppler echocardiogram		26 weeks
Secondary	Urinary heparan sulfate concentrations		26 weeks
Secondary	Urinary dermatan sulfate concentrations		26 weeks
Secondary	Serum heparan sulfate concentrations		26 weeks
Secondary	Serum dermatan sulfate concentrations		26 weeks